W Endoluminal Robotics
Early Diagnosis and Treatment of Lung Cancer
Company Overview
Snapshot
Founded in October 2020 by Prof. Nir Shvalb, W Endoluminal Robotics operates with 1–10 employees. The company has raised $260,000 across two funding rounds from one investor. In May 2023, the company secured additional funding from Peregrine Ventures.
Business overview
W Endoluminal Robotics is developing advanced robotic solutions for the early diagnosis and treatment of lung cancer. Their core technology involves novel mechanical solutions and sophisticated control algorithms designed to provide limitless accessibility within the lungs and enable real-time confirmation. The company's innovations aim to enhance certainty in lung biopsies and facilitate advanced lung treatment, serving the healthcare industry by offering an approach that reduces the burden on hospitals and surpasses existing advanced technologies.
Log in to access full profile ›Company Intelligence Q&A
- When was W Endoluminal Robotics founded?
- W Endoluminal Robotics was founded in October 2020.
- Who is a founder of W Endoluminal Robotics?
- Prof. Nir Shvalb is a founder of W Endoluminal Robotics.
- What is W Endoluminal Robotics' primary focus?
- W Endoluminal Robotics focuses on the early diagnosis and treatment of lung cancer through novel robotic solutions.
- What is the total capital raised by W Endoluminal Robotics?
- W Endoluminal Robotics has raised a total of $260,000.
- What is W Endoluminal Robotics developing?
- W Endoluminal Robotics is developing advanced robotic solutions for the early diagnosis and treatment of lung cancer.